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INTRODUCTION
In the 1970s, dramatic progress was made in developing
the technology that made it possible to recombine frag-
ments of DNA, so that it became feasible to move a gene
from one organism to another. Initial success in producing
human proteins such as insulin [1] and growth hormone [2]
in bacterial cells led to the hope that soon genetic diseases
such as sickle cell disease could be corrected by simply plac-
ing the normal gene into hematopoietic stem cells. Indeed,
after some pre l i m i n a ry encouraging results in mice, plas-
mids containing the herpesvirus thymidine kinase and
human b-globin gene DNA were injected into two tha-
lassemic patients with the hope that b-globin pro d u c t i o n
would be improved [3].
H o w e v e r, introducing genes into hematopoietic stem
cells outside the body could provide the greatest fle x i b i l i t y
in devising strategies to transduce cells and was the
approach considered to be most likely to succeed. Moreover,
it provided some reassurance to those who were opposed to
altering germ tissues. Because hematopoietic stem cells are
comparatively accessible, in both experimental animals and
humans, and hematopoietic stem cell transplantation pro-
vided an extensive background re g a rding the re g e n e r a t i o n
of hematopoietic organs after transplantation, the treatment
of hematologic disease became a favorite goal of would-be
gene therapists.
In spite of considerable initial optimism, however, the
therapeutic goals of gene therapy have not been achieved in
humans. Not a single patient has been shown to have bene-
fited from the insertion of genes into hematopoietic stem
cells. In this brief re v i e w, I examine some of the reasons for
this impasse and some of the possible solutions under active
investigation. Further details may be found in recent re v i e w
a rticles [4,5].
THERAPEUTIC INDICATIONS FOR THE TRANSFER OF
FOREIGN GENES INTO HEMATOPOIETIC STEM CELLS
The most straightforward indication for the transfer of
genes into hematopoietic stem cells is to correct an inherit-
ed disease in which the phenotype is expressed principally in
the progeny of hematopoietic stem cells. The effectiveness
of allogeneic transplantation in treating a disease constitutes
a valid test of the therapeutic result that could be expected
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ABSTRACT
For the past two decades, concerted eff o rts have been made to treat human disease by replacing nonfunctioning
genes in cells or by correcting mutations that produce disease. Successful application of these methods could lead to
e ffective therapies for a variety of genetic and acquired diseases, many of which are not treatable today. Genes can
be transferred into cells using either viral vectors, which have evolved the ability to bring their DNA into the host
cell, or nonviral vectors, which, until re c e n t l y, have been much less efficient in their ability to introduce exogenous
DNA into cells. Whereas cell transduction is possible in vivo, it is much simpler to accomplish in vitro; for this re a-
son the hematopoietic stem cell has been a favorite target in attempts to implement gene therapy. Stem cells can be
p a rtially purified from the blood or marro w, transduced with the gene of interest, and re i n t roduced into the body.
Any genetic disease that responds to transplantation would be expected also to respond to gene therapy. The
p ro g ress made over the past two decades has resulted in better vectors and ingenious new techniques for corre c t i n g
mutations in endogenous genes. Although effective gene therapy in humans has continued to be an elusive goal,
recent advances lead us to hope that this goal will be realized within the next few years.
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from gene transfer therapy. Table 1 gives some examples of
the hereditary stem cell diseases that have been treated suc-
cessfully by allogeneic transplantation. These disord e r s
therefore serve as examples of lymphocyte, red cell, granu-
locyte, and macrophage disorders in which gene therapy
would be effective. On the other hand, diseases in which
the p rogeny of hematopoietic stem cells are aff e c t e d
but i m p o rtant tissue manifestations are not corrected by
transplantation, such as hypoxanthine-guanine phosphori-
bosyltransferase deficiency, would not be expected to be cor-
rected by gene transfer to hematopoietic stem cells. 
Replacing a nonfunctioning gene would have the desire d
therapeutic effect in the case of deficiency disorders, such as
Gaucher disease or chronic granulomatous disease, pro v i d e d
that the level of expression was sufficiently high. Cert a i n l y
50% of expression, the level found in heterozygotes, would
be quite sufficient, but even much lower levels would likely
s u ffice. Enzyme replacement therapy of Gaucher disease is
associated with small [6], transient [7,8] increases of tissue
levels of glucocere b rosidase. These increases are successful
in reversing the course of the disease, but there are no mod-
els that allow accurate prediction of what level of expre s s i o n
would be needed. For optimal treatment of a disease such as
sickle cell disease, in which the abnormal gene product has
an unfavorable effect and there f o re needs to be removed to
achieve the desired therapeutic goal, a combination of tech-
nologies that involve destruction of the transcript of an
inherited mutation and introduction of the correct sequence
would be needed. Ingenious ribozyme-based or mismatch
repair–based methods have recently been devised for the
repair of sickle b-globin mRNA [9,10]. Another innovative
way in which genes may be controlled is by the transfer of a
s p e c i fically designed transcriptional re g u l a t o r, a zinc fin g e r
p rotein, that binds to a designated gene and regulates its out-
put [11]. Such designer genes could be used to turn off the
transcription of the sickle b-globin gene, on the one hand,
and to upregulate the g and d loci, on the other. Which, if
a n y, of these new methods will prove to be clinically applica-
ble is not clear, but it is apparent that there are ways in which
human genes may be modified, not simply introduced into
c e l l s .
Other potential indications for gene transfer are the
c o rrection of acquired genetic defects, specifically those
leading to neoplasia, and the treatment of infectious diseases
such as AIDS. The introduction of a gene that either coun-
teracts the effect of an oncogene or destroys its mRNA
would be such a therapeutic approach. Experimentally, this
method has been attempted by the introduction of antisense
genes [12] that, in effect, would neutralize the product of an
oncogene such as BCR/ABL, or by the introduction of a
ribozyme that cleaves the offending transcript [13]. Con-
structs that produce inhibitors of HIV could have promise
in the treatment of that infection [14].
HOW GENES ARE TRANSFERRED TO HEMATOPOIETIC
STEM CELLS
DNA can be transferred into cells using nonviral or viral
vectors. Over the past decade, the efficiency by which genes
can be introduced into cells using nonviral means has been
improved. The use of the very inefficient calcium hydroxide
precipitation method to transfect cells has been superseded
by much more efficient nonviral methods, including electro-
poration, cationic liposomes, cationic dentrimers, and his-
tones. Because viruses have evolved mechanisms to bring
their genetic material into cells, however, viral vectors are
generally much more efficient than nonviral methods. Some
of the genes essential for the viruses’ normal life cycle are
removed and the gene or cDNA of interest is inserted. The
essential genes that have been removed from the virus itself
a re introduced into cells that serve as “producer lines.”
They make the proteins that are required by the virus, but
the virus that is harvested lacks these genes and there f o re
cannot continue to replicate in the host. Retroviruses have
been used most frequently in gene transfer studies, but con-
siderable work has been done to adapt adeno-associated
viruses to this purpose. 
Not only the efficiency of gene transfer must be consid-
ered, but also whether the transferred genes are incorporat-
ed into the nuclear DNA. Nonviral transfection or infection
with adenovirus results in little or no integration of the
t r a n s f e rred DNA into the chromosomes of the host cells.
Instead, the DNA exists in episomal form and may function
for some weeks or even months but eventually is eliminated.
In contrast, retrovirus, lentivirus, and adeno-associated virus
vectors have mechanisms that integrate the transferre d
DNA into the chromosome of the host cell. As the cell
divides, the transferred DNA divides with the chromosome
into which it has integrated. For this reason, as well as their
relatively high effic i e n c y, these viral vectors have occupied
center stage in efforts to transfer genes into hematopoietic
stem cells. Table 2 summarizes the advantages and disadvan-
tages of some of the viral vectors that have been used for
gene transfer.
NUMBER OF TRANSDUCED HEMATOPOIETIC STEM CELLS 
The number of hematopoietic stem cells transduced is
the product of the number of hematopoietic stem cells tar-
geted and the transduction eff i c i e n c y. Even using modern
h a rvesting techniques that mobilize hematopoietic stem
cells, the number of hematopoietic stem cells obtained rep-
resents only a small percentage of the hematopoietic stem
cells in the body. Because hematopoietic stem cells are non-
dividing cells, the transduction efficiency is low. Therefore,
the number of transduced hematopoietic stem cells is very
small in relationship to the total number of hematopoietic
Table 1. Some hereditary diseases that have been successfully treated by
hematopoietic stem cell transplantation
Cell lineage most affected
in disease phenotype Disease
Lymphocyte Severe combined immunodeficiency
Erythron Thalassemia major
Erythron Sickle cell disease
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stem cells in the body. Even small numbers of cells, however,
may confer considerable benefit to patients with diseases
such as chronic granulomatous disease and adenosine deami-
nase defic i e n c y. For example, in chronic granulomatous dis-
ease it has been estimated that as few as 5% fully functioning
n e u t rophils could provide substantial protection against
infection and that oxidase activity as low as 3–5% in all of the
cells is associated with a mild phenotype [15]. In the case of
diseases in which there is no cell-to-cell correction, such as
thalassemia or Gaucher disease, however, no clinical benefit
can be expected unless a high pro p o rtion of the hemato-
poietic stem cells in the body have a functioning transgene.
INACTIVATION OF FOREIGN DNA
The transfer of DNA into a cell is not enough. It must be
transcribed and continue to be transcribed if long-term
e ffects are to be achieved. But evolution of higher org a n i s m s
has resulted in the development of mechanisms that thwart
this goal. The survival of a species depends on a balance
between fidelity and infidelity—the accurate re p roduction of
the genome on the one hand and sufficient numbers of muta-
tions to allow the variability that is needed to permit adapta-
tion to changing conditions, on the other. Of the changes in
DNA that may occur, the most drastic is incorporation of for-
eign sequences into the genome. No doubt such “horizontal”
transmission of DNA from one species to another is a con-
stantly re c u rring event [16,17]. Seawater, for example, must
contain large amounts of DNA from dying organisms, and
v i ruses are a highly honed method of introducing fore i g n
DNA into cells. The existence of mitochondria, pre s u m a b l y
derived from primitive bacteria, in all higher org a n i s m s
attests to the positive influence such introduction of exoge-
nous DNA can have. But in most cases, the introduction of
f o reign DNA will have disastrous effects, and it is part i c u l a r l y
species that have limited re p roductive capacity, such as H o m o
s a p i e n s, that must protect themselves against drastic changes
in their genome. Mechanisms for inactivating extern a l l y
i n t roduced fragments of DNA have there f o re evolved, part i c-
ularly in multipotential cells, and these must be overcome for
gene transfer to be successful. Although continued expre s s i o n
of genes introduced into mouse hematopoietic stem cells has
been achieved many times [18], this has not been the case
with human hematopoietic stem cells. 
SOME POTENTIAL SOLUTIONS
The search for better vectors has been a major goal of
those trying to develop clinically useful gene therapy.
Although there has been some progress, the enthusiasm for
each modification has been followed by disappointment.
Thus, each new development is greeted with only cautious
optimism. The recent development of lentivirus vectors
based on HIV [14] is encouraging, in that studies reported
so far suggests that this viral vector is able to escape inacti-
vation. If this finding holds true when the virus is used as a
vector in human trials, it would represent a major advance,
because gene inactivation is one of the major problems that
successful gene therapy faces. 
Even with efficient vectors that allow continued expres-
sion, gene therapy cannot succeed in the treatment of many
hematopoietic stem cell diseases without the availability of
larger numbers of hematopoietic stem cells. As pointed out
above, diseases such as Gaucher disease and sickle disease
demand that the transduced hematopoietic stem cells are the
great majority, not a small minority, of cells. One approach
to this problem is to amplify hematopoietic stem cells out-
side the body. Thus, so many hematopoietic stem cells could
be given that the majority of cells in the body carried the
transduced genes. So far, attempts to achieve significant
amplification of a self-renewing multipotential population
have failed. It is likely that some day this problem will be
overcome. The stem cell compartment does seem to repop-
ulate in humans after depletion, albeit slowly, suggesting
that a mechanism by which these cells can divide into larger
numbers of self-renewing cells exists. When we understand
how to amplify hematopoietic stem cells, major advances
will be possible, not only in gene transfer, but in all aspects
of stem cell transplantation. 
A second approach is to insert into the cell a gene that
provides a selective advantage when a drug is administered.
For example, a construct has been engineered that contains,
in addition to the glucocere b rosidase gene, the cDNA for
human P-glycoprotein (the multidrug resistance gene,
MDR1) as a selectable marker [19]. Drugs to which the lat-
ter gene produces resistance could be used to destroy non-
transduced hematopoietic stem cells, providing an opportu-
nity for the initially few transduced cells to become a major-
ity of the hematopoietic stem cells in the marrow.
Thus far, the results of gene therapy trials have been
disappointing to those of us who, 20 years ago, undere s t i-
mated the difficulties that needed to be overcome. Gradual-
l y, however, the problems that face us are being identifie d
and progress is being made in overcoming them. It should
not be too many more years before we can offer this new
t reatment modality to selected patients with genetic dis-
eases, neoplasia, or infections.
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